Levetiracetam monotherapy in children with epilepsy: Experience from a tertiary pediatric neurology center

YILDIRIM M., BEKTAŞ Ö., Goktas O. A., Yuksel M. F., Sahin S., TEBER S.

EPILEPSY & BEHAVIOR, cilt.116, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 116
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.yebeh.2020.107745
  • Dergi Adı: EPILEPSY & BEHAVIOR
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, EMBASE, MEDLINE, Psycinfo
  • Anahtar Kelimeler: Children, Discontinuation rate, Efficacy, Levetiracetam, Monotheraphy, Safety
  • Ankara Üniversitesi Adresli: Evet

Özet

Objectives: Levetiracetam (LEV) is a second-generation antiepileptic drug with high efficacy and tolerability in children and adults with epilepsy. We aimed to retrospectively assess the long-term efficacy, tolerability, and safety of LEV monotherapy in children with epilepsy.